[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617582":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":38,"studyPopulation":38,"armGroups":45,"interventions":52,"overallOfficials":38,"centralContacts":58,"locations":68,"responsibleParty":84,"collaborators":38,"id":86,"slug":38,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":38,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":38,"enrollmentInfo":94,"targetDuration":38,"studyType":97,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":71,"whyStopped":38,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Charles University, Czech Republic","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":38},[9,13],{"measure":10,"description":11,"timeFrame":12},"Changes in glycated haemoglobin (HbA1c)","Differences between HbA1c values in the Visit 0 and Visit 24","Up to 24 months",{"measure":14,"description":15,"timeFrame":12},"Changes in percentage of time in target ranges 3,9-10,0 mmol\u002FL (70-180 mg\u002Fdl)","Differences between percentage of time in target ranges in the Visit 0 and Visit 24",[17,20,23,26,29,32,35],{"measure":18,"description":19,"timeFrame":12},"Changes in percentage of time in hypoglycemic ranges \u003C3.9 mmol\u002FL (70 mg\u002Fdl) and \u003C3.0 mmol\u002FL (54 mg\u002Fdl)","Differences between percentage of time in hypoglycemic ranges in the Visit 0 and Visit 24",{"measure":21,"description":22,"timeFrame":12},"Changes in percentage of time in hyperglycemic ranges >10,0 mmol\u002FL (180 mg\u002Fdl) and >13,9 mmol\u002FL (250 mg\u002Fdl)","Differences between percentage of time in hyperglycemic ranges in the Visit 0 and Visit 24",{"measure":24,"description":25,"timeFrame":12},"Changes in percentage of time in tight target ranges 3,9-7,8 mmol\u002FL (70-140 mg\u002Fdl)","Differences between percentage of time in tight target ranges in the Visit 0 and Visit 24",{"measure":27,"description":28,"timeFrame":12},"Changes in average glycemia (mmol\u002FL)","Differences between average glycemia in the Visit 0 and Visit 24",{"measure":30,"description":31,"timeFrame":12},"Changes in estimated glycated haemoglobin GMI (%)","Differences between estimated glycated haemoglobin GMI in the Visit 0 and Visit 24",{"measure":33,"description":34,"timeFrame":12},"Changes in glycemic variability expressed as the coefficient of variation (%)","Differences between glycemic variability in the Visit 0 and Visit 24",{"measure":36,"description":37,"timeFrame":12},"Time spent in automated insulin delivery mode","Expressed as percentage of time",null,{"allocation":40,"interventionModel":41,"interventionModelDescription":38,"primaryPurpose":42,"observationalModel":38,"timePerspective":38,"maskingInfo":43},"NA","SINGLE_GROUP","TREATMENT",{"masking":44,"maskingDescription":38,"whoMasked":38},"NONE",[46],{"label":47,"type":48,"description":49,"interventionNames":50},"Patients with TouchCare Nano A8 insulin pump with the APGO system","EXPERIMENTAL","Patients with type 1 diabetes, who initiated use of the TouchCare Nano A8 insulin pump with the APGO system.",[51],"Device: Device: Insulin pump TouchCare Nano A8 with the APGO system",[53],{"type":54,"name":55,"description":56,"armGroupLabels":57,"otherNames":38},"DEVICE","Device: Insulin pump TouchCare Nano A8 with the APGO system","Insulin pump Medtrum TouchCare Nano A8 with the APGO algorithm is the only patch pump-based automated insulin delivery system available in the Czech Republic.",[47],[59,64],{"name":60,"role":61,"phone":62,"phoneExt":38,"email":63},"Jan Soupal","CONTACT","+420775654343","jan.soupal@seznam.cz",{"name":65,"role":61,"phone":66,"phoneExt":38,"email":67},"Dat Do","+420608220784","datdoquoc@seznam.cz",[69],{"facility":70,"status":71,"city":72,"state":38,"zip":38,"country":73,"countryCode":38,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia","RECRUITING","Prague","Czechia",{"type":75,"coordinates":76},"Point",[77,78],14.42076,50.08804,{"lat":78,"lon":77},[81,82],{"name":60,"role":61,"phone":62,"phoneExt":38,"email":63},{"name":60,"role":83,"phone":38,"phoneExt":38,"email":38},"PRINCIPAL_INVESTIGATOR",{"type":85,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100617582",false,"NCT07320495","Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery","Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery: The RENEW Study","Inclusion Criteria:\n\n* patients with T1D\n* type 1 diabetes for ≥1 years\n* ≥ 18 years old\n* written informed consent prior to starting study related activity\n\nExclusion Criteria:\n\n* severe noncompliance\n* lactation, pregnancy, intending to become pregnant during study\n* use of medication with effects on carbohydrate metabolism","ALL","18 Years",{"count":95,"type":96},200,"ESTIMATED","INTERVENTIONAL",[40],"The Medtrum TouchCare Nano system with the APGO algorithm is the only patch pump-based automated insulin delivery system available in the Czech Republic. However, until now, no prospective clinical study has evaluated its efficacy and safety under real-world conditions. The RENEW study is the first to address this topic.",[101],"Diabetes Mellitus Type 1",[103,104],"automated insulin delivery system","patch pump","2025-12-25",{"date":107,"type":108},"2026-01-06","ACTUAL",{"date":110,"type":108},"2025-06-19",{"date":112,"type":96},"2028-06-19",{"name":5,"class":6},1]